title: Medical resource use and costs among rheumatoid arthritis patients receiving disease-modifying antirheumatic drug therapy.
abstract: OBJECTIVE
  To identify costs among rheumatoid arthritis (RA) patients receiving alternative disease-modifying antirheumatic drug (DMARD) therapies.
  
  
  METHODS
  Using managed care organization data, we identified members who (a) were prescribed any DMARD therapy for two consecutive months between July 1993 and February 1998, (b) were aged > or = 18 years, (c) had > or = 6 months of DMARD-free enrollment prior to the first DMARD, and (d) had a diagnosis of RA.
  
  
  RESULTS
  The average age of the cohort (n = 571) was 51 years, and 70% were women. Mean duration of enrollment following initiation of DMARD therapy (observation period) was 19.5 months; 28.8% of patients switched DMARD regimens. The average monthly cost of care was $853, of which $294 (34%) was for RA-coded medical services. Monthly RA-coded costs varied by DMARD: hydroxychloroquine $227 (n = 252), methotrexate $340 (n = 185); sulfasalazine $233 (n = 49), and other mono/combination therapy $425 (n = 85) (P = 0.001).
  
  
  CONCLUSIONS
  Costs of RA-coded care in patients receiving DMARDs are low and vary by DMARD.
authors.affiliation: Project HOPE Center for Health Affairs, 7500 Old Georgetown Road, Suite 600, Bethesda, MD 20814-6133, USA.
authors.forename: R I
authors.initials: RI
authors.lastname: Griffiths
authors.forename: M
authors.initials: M
authors.lastname: Bar-Din
authors.forename: C H
authors.initials: CH
authors.lastname: MacLean
authors.forename: E M
authors.initials: EM
authors.lastname: Sullivan
authors.forename: R J
authors.initials: RJ
authors.lastname: Herbert
authors.forename: E H
authors.initials: EH
authors.lastname: Yelin
mesh_terms: D018501:Antirheumatic Agents / Q000191:economics / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000191:economics*; D004180:Direct Service Costs / Q000706:statistics & numerical data; D016527:Drug Costs; D004359:Drug Therapy, Combination; D005260:Female; D017048:Health Care Costs / Q000706:statistics & numerical data; D006295:Health Resources / Q000191:economics* / Q000706:statistics & numerical data*; D006302:Health Services Research; D006801:Humans; D006886:Hydroxychloroquine / Q000627:therapeutic use; D008297:Male; D008329:Managed Care Programs / Q000191:economics / Q000706:statistics & numerical data; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D015146:Midwestern United States; D009511:New England; D012460:Sulfasalazine / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D018501:Antirheumatic Agents; D012460:Sulfasalazine; D006886:Hydroxychloroquine; D008727:Methotrexate